Noxopharm Ltd. · ASX:NOX

Noxopharm — Ausbiotech Asia Series March 2019

23 slides from Noxopharm's conference presentation, March 2019

1. Slide 1: March 2019 - Discover Develop Deliver

   March 2019 DISCOVER DEVELOP DELIVER ASX: NOX 1 ©2019 Noxopharm

2. Slide 2: Disclaimer

   Disclaimer This presentation has been prepared by Noxopharm Limited (NOX or the Company). It should not be considered as an offer or invitation to subscribe for or purchase any shares in NOX or as an inducement to purchase any shares in NOX. No agreement to subscribe for securities in the NOX will b

3. Slide 3: We have a single objective: to bring Veyonda to market

   We have a single objective: To bring Veyonda ® → to market → as the first approved drug → that makes radiotherapy more effective → for all forms of radiotherapy → across most forms of solid cancer → shifting the effect of radiotherapy from palliative to more curative. 3 ©2019 Noxopharm

4. Slide 4: Veyonda: A new class of anti-cancer drug

   Veyonda® A new class of anti-cancer drug A dual radio-enhancing/immuno-oncology drug Helping radiotherapy kill more cancer cells Activating the innate immune system to eradicate all cancer cells in the body 4 ©2019 Noxopharm

5. Slide 5: Radiation seeks to kill cancer cells by damaging DNA

   Veyonda® A new class of anti-cancer drug Radiation seeks to kill cancer cells by damaging DNA 5 ©2019 Noxopharm

6. Slide 6: Radiation leaves a mixture of dead, damaged and undamaged cells

   Veyonda® A new class of anti-cancer drug Radiation seeks to kill cancer cells by damaging DNA Non-irradiated lesions unaffected Resulting mixture of dead, damaged and undamaged cancer cells 6 ©2019 Noxopharm

7. Slide 7: Damaged cells can repair and survive

   Veyonda® A new class of anti-cancer drug Radiation seeks to kill cancer cells by damaging DNA A proportion of damaged cells successfully repair the damage and survive 7 ©2019 Noxopharm

8. Slide 8: Veyonda: more cancer cells killed

   Veyonda® A new class of anti-cancer drug A dual radio-enhancing/immuno-oncology drug Veyonda® + More cancer cells killed 8 ©2019 Noxopharm

9. Slide 9: Veyonda: greater shrinkage of the lesion

   Veyonda® A new class of anti-cancer drug A dual radio-enhancing/immuno-oncology drug Veyonda® + Result is greater More cancer cells killed shrinkage of the lesion 9 ©2019 Noxopharm

10. Slide 10: Veyonda: immune cell activation

    Veyonda® A new class of anti-cancer drug A dual radio-enhancing/immuno-oncology drug Veyonda® + • Natural Killer cells • CD4 T lymphocytes 10 ©2019 Noxopharm

11. Slide 11: Innate immune cells stimulated in irradiated and non-irradiated lesions

    Veyonda® A new class of anti-cancer drug A dual radio-enhancing/immuno-oncology drug Veyonda® + Innate immune cells stimulated both within the irradiated lesion and more generally, resulting in shrinkage of both the irradiated and non-irradiated lesions • Natural Killer cells • CD4 T lymphocytes 11

12. Slide 12: Initial focus on end-stage prostate cancer

    Veyonda® Initial focus on end-stage prostate cancer Failed all standard treatments Progressive disease (rising PSA) Cancer metastatic; mostly in bones Bone pain; high opioid use Survival typically 3-6 months 12 ©2019 Noxopharm

13. Slide 13: Veyonda + Radiotherapy in end-stage prostate cancer

    Veyonda® + Radiotherapy in end-stage prostate cancer Externally-delivered radiotherapy Veyonda® 10 days Radiotherapy 5 days 13 ©2019 Noxopharm

14. Slide 14: DARRT: Direct and Abscopal Response to Radio-Therapy

    DARRT Direct and Abscopal Response to Radio-Therapy DIRECT RESPONSE ABSCOPAL RESPONSE At a minimum, Veyonda® is expected to lead to The best expected outcome would be an improved better DIRECT response to radiotherapy due DIRECT response, plus shrinkage of non-targeted lesions to a radio-enhancing e

15. Slide 15: Case Study #1

    Case Study #1 15 ©2019 Noxopharm

16. Slide 16: Case Study #1

    Case Study #1 16 ©2019 Noxopharm

17. Slide 17: Case Study #1

    Case Study #1 17 ©2019 Noxopharm

18. Slide 18: Case Study #1

    Case Study #1 Veyonda + 20 Gy radiotherapy 7/7/14 29/9/14 28/11/14 2/3/15 30/4/15 Total PSA 140 170 13 0.18 0.07 February 2019 = PSA undetectable; no lesions detected 18 Data on File – collected with consent of patient ©2019 Noxopharm

19. Slide 19: DARRT-1 Study

    DARRT-1 Study v Phase 1b study; 24 men v Patients reviewed at 6, 12 and 24 weeks v Interim review of first 7 patients at 12 weeks* • 4/7 achieved PSA falls >50% • 5/7 achieved decrease in pain levels >30% • 1/7 showed partial response (RECIST) and 5/7 showed stable disease The significant reductions

20. Slide 20: Veyonda - DARRT Treatment

    Veyonda® - DARRT Treatment v 10 days of treatment (vs 6-8 months chemotherapy) v Using low dose of radiation (one-third normal dose) v Well tolerated - fatigue only known side-effect (no typical chemotherapy side-effects) v Radiation delivered by readily-available standard external beam machines v C

21. Slide 21: Key Messages

    Key Messages WE BELIEVE VEYONDA HAS THE POTENTIAL TO BECOME A MAJOR ONCOLOGY DRUG A SUCCESSFUL OUTCOME BEING A SHARE OF THE $100 BILLION ONCOLOGY DRUG MARKET DELIVERING COST-EFFECTIVE TREATMENT IN A WELL-TOLERATED WAY POTENTIALLY PROVIDING CONSIDERABLY GREATER BENEFITS THAN WITH CHEMOTHERAPY ü Exper

22. Slide 22: Key metrics

    Key metrics Number of Shares 121.9M : Free float 66.8% Market Cap (1 March 2019) AU$53M IPO price 20 cents CEO Directors 12 month high/low $1.64/0.36 Others Cash position AU$ 9.6M (31 Dec 2018) 22 ©2019 Noxopharm

23. Slide 23: ASX: NOX

    [email protected] ASX: NOX 23 ©2019 Noxopharm

Noxopharm — Ausbiotech Asia Series March 2019 on 6ix